ZURCHER KANTONALBANK FINANCE (GUERNSEY) LIMITED

Zurcher Kantonalbank Finance (Guernsey) Limited Share Price

Certificat

Z0980Z

CH1329111327

Market Closed - Swiss Exchange 16:20:00 24/05/2024 BST
95.97 ^USD	-.--%

1 month

-2.77%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart Zurcher Kantonalbank Finance (Guernsey) Limited

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	06-02	RE
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	06-01	BU
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	05-30	MT

More news

Static data

Product type	Obligations Convertibles
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	ZKB
	Z0980Z
ISIN	CH1329111327
Date issued	11/03/2024
Strike	54.36 $
Maturity	11/03/2025 (282 Days)
Parity	0.05 : 1
Emission price	100 $
Emission volume	N/A
Settlement	les deux
Currency	USD

Technical Indicators

Highest since issue	101.6 $
Lowest since issue	95.97 $

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company